NCT03798678 2026-04-13
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
51 trialsNCT04108195 2026-04-13
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04667663 2026-04-13
CPD-DARA
Cancer Trials Ireland
Phase 1 Active not recruiting
NCT04722146 2026-04-13
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05050097 2026-04-13
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05675449 2026-04-13
MagnetisMM-20
Pfizer
Phase 1 Active not recruiting
NCT06425991 2026-04-13
MajesTEC-10
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04684108 2026-04-07
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1 Active not recruiting
NCT05411497 2026-04-03
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Active not recruiting
NCT06223516 2026-03-27
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Active not recruiting
NCT04756726 2026-03-25
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
C4 Therapeutics, Inc.
Phase 1 Active not recruiting
NCT04910568 2026-03-19
CAMMA 1
Genentech, Inc.
Phase 1 Active not recruiting
NCT03091257 2026-03-13
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT06203912 2026-03-05
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03070327 2026-03-04
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03741127 2026-03-04
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Poseida Therapeutics, Inc.
Phase 1 Active not recruiting
NCT05024045 2026-03-03
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
Phase 1 Active not recruiting
NCT03602612 2026-02-25
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT05556798 2026-02-24
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05577000 2026-02-20
Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Active not recruiting
NCT05391750 2026-02-17
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
Emory University
Phase 1 Active not recruiting
NCT05646836 2026-02-17
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Genentech, Inc.
Phase 1 Active not recruiting
NCT06325748 2026-02-12
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
Senti Biosciences
Phase 1 Active not recruiting
NCT04155749 2026-02-11
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Gilead Sciences
Phase 1 Active not recruiting
NCT01562405 2026-01-14
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT04640779 2026-01-06
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Active not recruiting
NCT05259839 2025-12-19
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
AbbVie
Phase 1 Active not recruiting
NCT05775094 2025-12-19
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04184050 2025-12-05
MK-4002-001
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Active not recruiting
NCT04091126 2025-11-28
DREAMM 9
GlaxoSmithKline
Phase 1 Active not recruiting
NCT05139225 2025-11-04
A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT00881920 2025-10-21
CHARKALL
Baylor College of Medicine
Phase 1 Active not recruiting
NCT02909036 2025-10-10
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05688475 2025-10-08
A Rollover Study of CC-122
Bristol-Myers Squibb
Phase 1 Active not recruiting
NCT04555551 2025-09-22
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05823571 2025-09-18
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT06381141 2025-09-18
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
Cullinan Therapeutics Inc.
Phase 1 Active not recruiting
NCT03672318 2025-09-16
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05308654 2025-08-14
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
AbbVie
Phase 1 Active not recruiting
NCT05286229 2025-08-08
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
AbbVie
Phase 1 Active not recruiting
NCT05431608 2025-07-09
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03549442 2025-06-26
Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
University of Pennsylvania
Phase 1 Active not recruiting
NCT05320809 2025-05-29
Study of 3D189 in Patients With Hematologic Malignancies
3D Medicines
Phase 1 Active not recruiting
NCT04398745 2025-05-23
DREAMM12
GlaxoSmithKline
Phase 1 Active not recruiting
NCT04354246 2025-05-22
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
Phase 1 Active not recruiting
NCT02334865 2025-05-11
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Roswell Park Cancer Institute
Phase 1 Active not recruiting
NCT02332850 2025-05-01
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Active not recruiting
NCT06163898 2025-04-04
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene
Phase 1 Active not recruiting
NCT04613557 2023-08-31
IMMUNICY-1
Celyad Oncology SA
Phase 1 Active not recruiting
NCT04093596 2023-08-14
UNIVERSAL
Allogene Therapeutics
Phase 1 Active not recruiting